Pfizer Leukmia Drug Success $PFE $XHS

Pfizer has annouced that its phase 3 study trials of treatment of inotuzumab ozogamicin met its first primary endpoint of demonstrating a higher complete hematologic remission rate in adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia (ALL) compared to that achieved with standard of care chemotherapy.

The above success conjugates a new drug for Leukemia.

View the full release here.